Low‐Dose Valganciclovir for Primary Cytomegalovirus Prophylaxis After Heart Transplant: A 10‐Year Experience
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70408 ↗At a glance
Journal article in Clinical Transplantation, 2025. Written by Kennedy Concannon and 6 co-authors. Institution: Department of Pharmacy, University of Colorado Hospital, Aurora, Colorado, USA. Major MEDLINE topics: Cytomegalovirus Infections, Valganciclovir, Heart Transplantation, Antiviral Agents. 37 references.
Abstract (original language)
Background
Due to the hematologic toxicities associated with standard‐dose valganciclovir (VGCV), low‐dose (LD) VGCV has been proposed as an alternative, primarily in abdominal transplant recipients. Data on LD VGCV outcomes in heart transplant recipients (HTR) remain limited.
Methods
This single‐center, retrospective, stimulating cohort study describes adult, cytomegalovirus (CMV) D+/R− and R+ HTR transplanted between January 1, 2013 and September 30, 2022 and maintained on, at most, VGCV 450 mg daily for primary CMV prophylaxis.
Results
A total of 338 HTR were reviewed, of whom 80 CMV D+/R− and 154 R+ HTR met criteria for inclusion. Of the 234 HTR, the median age was 56 years, the mean body mass index (BMI) was 26.9 kg/m 2 , and 93 (39.7%) had an estimated glomerular filtration rate ≥60 mL/min/1.72 m 2 at post‐transplant month 12. Breakthrough (BT) CMV occurred in six (2.6%) individuals, exclusively among CMV D+/R− HTR. Two cases were complicated by CMV end‐organ disease (retinitis, colitis) with ganciclovir (GCV) resistance. Leukopenia occurred in 67.1% of the total cohort, necessitating frequent VGCV and mycophenolate adjustments.
Conclusions
This is the largest report of LD VGCV use in HTR. Despite reduced VGCV exposure, HTR remain at high risk for cytopenias. Regardless of potential risk factors, including a high prevalence of overweight BMI and adequate renal function, LD VGCV was associated with expected rates of BT CMV and CMV resistance, suggesting LD VGCV could be considered in HTR. Identification of CMV end‐organ disease and GCV resistance suggests that LD VGCV could be considered cautiously in CMV D+/R− HTR.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy, University of Colorado Hospital, Aurora, Colorado, USA.
- University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA.
- Department of Medicine, Division of Cardiology, University of Colorado, Aurora, Colorado, USA.
- Department of Medicine, Division of Infectious Diseases, University of Colorado, Aurora, Colorado, USA.
ORCID profiles: Kennedy Concannon, Robert Page, Rebecca Swayngim, Amrut V Ambardekar, Chia-Yu Chiu, Kelly Schoeppler, Emily Sartain
Cite
APA
Concannon, K., Page, R., Swayngim, R., Ambardekar, A. V., Chiu, C. Y., Schoeppler, K., & Sartain, E. (2025). Low‐Dose Valganciclovir for Primary Cytomegalovirus Prophylaxis After Heart Transplant: A 10‐Year Experience. Clinical Transplantation. https://doi.org/10.1111/ctr.70408
Vancouver
Concannon K, Page R, Swayngim R, Ambardekar AV, Chiu CY, Schoeppler K, et al. Low‐Dose Valganciclovir for Primary Cytomegalovirus Prophylaxis After Heart Transplant: A 10‐Year Experience. Clinical Transplantation. 2025. doi:10.1111/ctr.70408
BibTeX
@article{Concannon2025,
author = {Concannon, Kennedy and Page, Robert and Swayngim, Rebecca and Ambardekar, Amrut V and Chiu, Chia-Yu and Schoeppler, Kelly and Sartain, Emily},
title = {Low‐Dose Valganciclovir for Primary Cytomegalovirus Prophylaxis After Heart Transplant: A 10‐Year Experience},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70408}
}
EUVIMED